As on 06-Dec-2023 16:00 EST
$32.50
$32.40
$32.83
$31.56
347,280
$17.49 - 33.39
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
Mirum Pharmaceuticals (MIRM)
| 61.95 | 5.27 | 14.34 | 72.29 | 9.58 | -- | -- |
S&P BSE Sensex*
| 14.36 | 7.11 | 5.61 | 11.10 | 15.57 | 14.53 | 12.73 |
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
2022
|
2021
|
2020
|
|
---|---|---|---|
Mirum Pharmaceuticals (MIRM)
| 22.26 | -8.65 | -28.79 |
S&P Small-Cap 600
| -17.42 | 25.27 | 9.57 |
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
The total asset value of Mirum Pharmaceuticals Inc. (MIRM) stood at $ 382 Mln as on 31-Mar-23
The share price of Mirum Pharmaceuticals Inc. (MIRM) is $31.58 (NASDAQ) as of 06-Dec-2023 16:00 EST. Mirum Pharmaceuticals Inc. (MIRM) has given a return of 9.58% in the last 3 years.
Mirum Pharmaceuticals Inc. (MIRM) has a market capitalisation of $ 1,040 Mln as on 23-Jun-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Mirum Pharmaceuticals Inc. (MIRM) is 3.96 times as on 23-Jun-2023, a 0.56% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Mirum Pharmaceuticals Inc. (MIRM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mirum Pharmaceuticals Inc. (MIRM) and enter the required number of quantities and click on buy to purchase the shares of Mirum Pharmaceuticals Inc. (MIRM).
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
The CEO & director of Mr. Christopher Peetz. is Mirum Pharmaceuticals Inc. (MIRM), and CFO & Sr. VP is Dr. Ian Clements.
The promoters of Mirum Pharmaceuticals Inc. (MIRM) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
132
|
|
104
|
|
83
|
|
81
|
Mirum Pharmaceuticals Inc. (MIRM) | Ratios |
---|---|
Return on equity(%)
|
-83.23
|
Return on capital employed(%)
|
--
|
Debt-to-equity ratio
|
0
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Mirum Pharmaceuticals Inc. (MIRM) was $-129 Mln.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug... for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California. Read more
Sign up and get access to:
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.